Published in

American Society for Clinical Investigation, Journal of Clinical Investigation, 11(110), p. 1619-1628, 2002

DOI: 10.1172/jci0215621

American Society for Clinical Investigation, Journal of Clinical Investigation, 11(110), p. 1619-1628

DOI: 10.1172/jci200215621

American Society for Clinical Investigation, Journal of Clinical Investigation, 11(110), p. 1619-1628

DOI: 10.1172/jci15621

Links

Tools

Export citation

Search in Google Scholar

Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Interactions between endothelial cells (ECs) and perivascular mural cells (MCs) via signaling molecules or physical contacts are implicated both in vascular remodeling and maintenance of vascular integrity. However, it remains unclear how MCs regulate the morphogenic activity of ECs to form an organized vascular architecture, comprising distinct artery, vein, and capillary, from a simple mesh-like network. A clear elucidation of this question requires an experimental model system in which ECs are separated from MCs and yet form vascular structures. Here we report that injection of an antagonistic mAb against PDGFR-beta into murine neonates provides such an experimental system in the retina by completely blocking MC recruitment to developing vessels. While a vascular network was formed even in the absence of MCs, it was poorly remodeled and leaky. Using this vascular system ideal for direct assessment of the activities of MC-derived molecules, we show that addition of recombinant modified angiopoietin-1 restored a hierarchical vasculature, and also rescued retinal edema and hemorrhage in the complete absence of MCs. These observations demonstrate the potential of Ang1 as a new therapeutic modality for MC dropout in diseases such as diabetic retinopathies.